SEC Filing Summary: Synaptogenix, Inc. (SNPX)
Business Context and Reporting Period
This Form 8-K Current Report, dated November 17, 2022, details a material definitive agreement entered into by Synaptogenix, Inc. (the "Company"). The Company is an emerging growth company incorporated in Delaware with its principal executive offices in New York. The filing announces a private placement transaction expected to close on November 21, 2022.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of Series B Convertible Preferred Stock and Warrants.
- Gross Proceeds: Expected to be $15 million.
- Securities Issued:
- 15,000 shares of Series B Convertible Preferred Stock (stated value $1,000 per share).
- Warrants to acquire up to 1,935,485 shares of Common Stock.
- Conversion/Exercise Price: $7.75 per share for both Preferred Stock conversion and Warrant exercise.
- Placement Agent Fees: 7% cash fee of gross proceeds plus warrants equal to 3% of the initial conversion shares.
- Use of Proceeds: General corporate purposes.
- Financial Statements: This filing does not contain audited revenue, profit, cash flow, or margin data. It focuses solely on the capital raise transaction.
Material Changes and Terms
The filing discloses significant changes to the Company's capital structure and obligations:
- Redemption Obligation: The Company must redeem the Preferred Shares in 15 equal monthly installments commencing April 1, 2023. Payments may be made in cash or shares, subject to specific pricing limitations.
- Dividend Terms: Preferred Shares accrue dividends at 7% per annum, compounded monthly. In the event of a "Triggering Event" (e.g., failure to file a registration statement or failure to pay amounts due), the dividend rate increases to 15% per annum.
- Forced Conversion: The Company may force conversion if the Common Stock closing price exceeds $11.625 for 20 consecutive trading days with sufficient volume.
- Registration Rights: The Company must file a resale registration statement covering 200% of the Conversion Shares and Warrant Shares within 30 days of the closing, with liquidated damages for failure to comply.
- Stockholder Approval: The Company agreed to seek stockholder approval for the issuance of shares exceeding 19.9% of outstanding Common Stock by March 1, 2023, to comply with Nasdaq listing standards.
Outlook, Risks, and Contingencies
- Liquidity Risk: The Company faces a mandatory redemption schedule starting in April 2023, creating a near-term cash outflow obligation unless settled in stock (subject to price floors and caps).
- Dilution Risk: The transaction includes a "full ratchet" anti-dilution provision for the Warrants and price-based adjustments for the Preferred Stock, which could significantly increase the number of shares issued if the Company raises capital at a lower price in the future.
- Triggering Events: Failure to maintain an effective registration statement or pay dividends/redemptions on time constitutes a Triggering Event, allowing holders to demand immediate cash redemption at a premium and increasing the dividend rate to 15%.
- Market Conditions: The ability to settle obligations in stock is limited by Nasdaq listing rules and beneficial ownership limitations.
Investor Verification Checklist
- Verify the Company's current cash position and ability to meet the first redemption payment due April 1, 2023.
- Confirm the status of the resale registration statement filing required within 30 days of the closing.
- Review the Company's recent stock price history to assess the likelihood of the forced conversion trigger ($11.625) or the stock settlement price floor ($1.55).
- Monitor the Company's announcement regarding the stockholder meeting scheduled no later than March 1, 2023, for Nasdaq compliance approval.
- Assess the potential dilution impact of the "full ratchet" provision if the Company conducts future equity raises below $7.75 per share.